Ketoconazole

Medical uses

Topical antifungal

Topically administered ketoconazole is usually prescribed for fungal infections of the skin and mucous membranes, such as athlete's foot, ringworm, candidiasis (yeast infection or thrush), jock itch, and tinea versicolor. Topical ketoconazole is also used as a treatment for dandruff (seborrheic dermatitis of the scalp) and for seborrheic dermatitis on other areas of the body, perhaps acting in these conditions by suppressing levels of the fungus Malassezia furfur on the skin.

Systemic antifungal

Ketoconazole has activity against many kinds of fungi that may cause human disease, such as Candida, Histoplasma, Coccidioides, and Blastomyces (although it is not active against Aspergillus), chromomycosis and paracoccidioidomycosis.

Ketoconazole is used orally in dosages of 200 to 400 mg per day in the treatment of superficial and deep fungal infections.

Off-label uses

Hair loss

Ketoconazole shampoo in conjunction with an oral 5α-reductase inhibitor such as finasteride or dutasteride has been used off label to treat androgenic alopecia. It was speculated that antifungal properties of ketoconazole reduce scalp microflora and consequently may reduce follicular inflammation that contributes to alopecia.

Limited clinical studies suggest ketoconazole shampoo used either alone or in combination with other treatments may be useful in reducing hair loss in some cases. However, one study found that applying a 2% Topical Ketoconazole solution on the balding scalps of women found comparable regrowth to 2% Minoxidil, albeit with a longer onset of action.

Hormonal

The side effects of ketoconazole are sometimes harnessed in the treatment of non-fungal conditions. While ketoconazole blocks the synthesis of the sterol ergosterol in fungi, in humans, at high dosages (800 mg/day), it potently inhibits the activity of several enzymes necessary for the conversion of cholesterol to steroid hormones such as testosterone and cortisol. All of these enzymes are mitochondrial cytochrome p450 enzymes. Based on these antiandrogen and antiglucocorticoid effects, ketoconazole has been used with some success as a second-line treatment for certain forms of advanced prostate cancer and for the suppression of glucocorticoid synthesis in the treatment of Cushing's syndrome. However, in the treatment of prostate cancer, concomitant glucocorticoid administration is needed to prevent adrenal insufficiency. Ketoconazole has additionally been used, in lower dosages, to treat hirsutism and, in combination with a GnRH analogue, male-limited precocious puberty. In any case, the risk of hepatotoxicity with ketoconazole limits its use in all of these indications, especially in those that are benign such as hirsutism.

Ketoconazole has been used to prevent the testosterone flare at the initiation of GnRH agonist therapy in men with prostate cancer.

Contraindications

Oral ketoconazole has various contraindications, such as concomitant use with certain other drugs due to known drug interactions. Other contraindications of oral ketoconazole include liver disease, adrenal insufficiency, and known hypersensitivity to oral ketoconazole.

Side effects

Gastrointestinal

Vomiting, diarrhea, nausea, constipation, abdominal pain, upper abdominal pain, dry mouth, dysgeusia, dyspepsia, flatulence, tongue discoloration may occur.

Endocrine

The drug may cause adrenal insufficiency so the level of the adrenocortical hormones should be monitored while taking it.

Liver

In July 2013, the US Food and Drug Administration (FDA) issued a warning that taking ketoconazole by mouth can cause severe liver injuries and adrenal gland problems: adrenal insufficiency and worsening of other diseases related to the gland conditions. It recommends oral tablets should not be a first-line treatment for any fungal infection. It should be used for the treatment of certain fungal infections, known as endemic mycoses, only when alternative antifungal therapies are not available or not tolerated. As contraindication it should not be used in people with acute or chronic liver disease.

Hypersensitivity

Anaphylaxis after the first dose may occur. Other cases of hypersensitivity include urticaria.

Topical formulations

The topical formulations have not been associated with liver damage, adrenal problems, or drug interactions. These formulations include creams, shampoos, foams, and gels applied to the skin, unlike the ketoconazole tablets, which are taken by mouth.

Pregnancy

Ketoconazole is categorized as pregnancy category C(Risk not ruled out) in the US. A subsequent trial in Europe failed to show a risk to infants of mothers receiving ketoconazole.

Overdose

In the event of an overdose of oral ketoconazole, treatment should be supportive and based on symptoms. Activated charcoal may be administered within the first hour following overdose of oral ketoconazole.

Interactions

The concomitant use of the following medications are contraindicated with ketoconazole tablets:

• methadone, disopyramide, dronedarone
• irinotecan, lurasidone, colchicine
• alprazolam, oral midazolam, oral triazolam
• felodipine, ranolazine, tolvaptan, eplerenone
• HMG-CoA reductase inhibitors: lovastatin, simvastatin
• ergot alkaloids: ergotamine, dihydroergotamine, ergometrine, methylergometrine
• Others: cisapride, nisoldipine, dofetilide, pimozide

The following medications are not recommended with ketoconazole:

• carbamazepine, phenytoin
• gastric acid suppressants: antacids, antimuscarinics, histamine H2 blockers, proton pump inhibitors
• sucralfate
• rifampin, rifabutin, isoniazid
• efavirenz, nevirapine

Ritonavir(an antiretrovial medication), is known for increasing the activity of ketoconazole. So it is recommended to reduce dosage.

There is also a list of drugs which significantly decrease systemic exposure to the ketoconazole and drugs whose systemic exposure is increased by the ketoconazole.

Pharmacology

Pharmacodynamics

Antifungal activity

As an antifungal, ketoconazole is structurally similar to imidazole, and interferes with the fungal synthesis of ergosterol, a constituent of fungal cell membranes, as well as certain enzymes. As with all azole antifungal agents, ketoconazole works principally by inhibiting the enzyme cytochrome P450 14α-demethylase (CYP51A1). This enzyme participates in the sterol biosynthesis pathway that leads from lanosterol to ergosterol. Lower doses of fluconazole and itraconazole are required to kill fungi compared to ketoconazole, as they have been found to have a greater affinity for fungal cell membranes.

Resistance to ketoconazole has been observed in a number of clinical fungal isolates, including Candida albicans. Experimentally, resistance usually arises as a result of mutations in the sterol biosynthesis pathway. Defects in the sterol 5-6 desaturase enzyme reduce the toxic effects of azole inhibition of the 14-alpha demethylation step. Multidrug-resistance (MDR) genes can also play a role in reducing cellular levels of the drug. As azole antifungals all act at the same point in the sterol pathway, resistant isolates are normally cross-resistant to all members of the azole family.

Antihormonal activity

As an antiandrogen, ketoconazole operates through at least two mechanisms of action. First, and most notably, high oral doses of ketoconazole (e.g. 400 mg three times per day) block both testicular and adrenal androgen biosynthesis, leading to a reduction in circulating testosterone levels. It produces this effect through inhibition of 17α-hydroxylase and 17,20-lyase, which are involved in the synthesis and degradation of steroids, including the precursors of testosterone. Due to its efficacy at reducing systemic androgen levels, ketoconazole has been used with some success as a treatment for androgen-dependent prostate cancer. Second, ketoconazole is an androgen receptor antagonist, competing with androgens such as testosterone and dihydrotestosterone (DHT) for binding to the androgen receptor. This effect is thought to be quite weak however, even with high oral doses of ketoconazole.

Ketoconazole, along with miconazole, has been found to act as an antagonist of the glucocorticoid receptor.

Ketoconazole is a racemic mixture consisting of cis-(2S,4R)-(−) and cis-(2R,4S)-(+) enantiomers. The cis-(2S,4R) isomer was more potent in inhibiting progesterone 17α,20-lyase than its enantiomer (IC50 values of 0.05 and 2.38 μM, respectively) and in inhibiting 11β-hydroxylase (IC50 values of 0.152 and 0.608 μM, respectively). Both isomers were relatively weak inhibitors of human placental aromatase.

Oral ketoconazole has been used clinically as a steroidogenesis inhibitor in men, women, and children at dosages of 200 to 1,200 mg/day. Numerous small studies have investigated the effects of oral ketoconazole on hormone levels in humans. It has been found in men to significantly decrease testosterone and estradiol levels and to significantly increase luteinizing hormone, progesterone, and 17α-hydroxyprogesterone levels, whereas levels of androstenedione, follicle-stimulating hormone, and prolactin were unaffected. The ratio of testosterone to estradiol is also decreased during oral ketoconazole therapy in men. Suppression of testosterone levels by ketoconazole is generally partial and has often been found to be transient. Better effects on suppression of testosterone levels have been observed in men when ketoconazole is combined with a GnRH agonist to suppress the hypothalamic–pituitary–gonadal axis, which prevents compensatory upregulation of luteinizing hormone secretion and consequent activation of gonadal testosterone production. In premenopausal women with polycystic ovary syndrome, ketoconazole has been found to significantly decrease levels of androstenedione and testosterone and significantly increase levels of 17α-hydroxyprogesterone and estradiol. Studies in postmenopausal women with breast cancer have found that ketoconazole significantly decreases androstenedione levels, slightly decreases estradiol levels, and does not affect estrone levels. This indicates minimal inhibition of aromatase by ketoconazole in vivo in humans. Ketoconazole has also been found to decrease levels of endogenous corticosteroids, such as cortisol, corticosterone, and aldosterone, as well as vitamin D.

Ketoconazole has been found to displace dihydrotestosterone and estradiol from sex hormone-binding globulin in vitro, but this was not found to be relevant in vivo.

Other activities

Ketoconazole has been found to inhibit the activity of the cation channel TRPM5.

Pharmacokinetics

When administered orally, ketoconazole is best absorbed at highly acidic levels, so antacids or other causes of decreased stomach acid levels will lower the drug's absorption. Absorption can be increased by taking it with an acidic beverage, such as cola. Ketoconazole is very lipophilic and tends to accumulate in fatty tissues.

Chemistry

Ketoconazole is a synthetic imidazole. It is a nonsteroidal compound. It is a racemic mixture of two enantiomers, levoketoconazole ((2S,4R)-(−)-ketoconazole) and dextroketoconazole ((2R,4S)-(+)-ketoconazole). Levoketoconazole is under development for potential clinical use as a steroidogenesis inhibitor with better tolerability and less toxicity than ketoconazole. Other steroidogenesis inhibitors besides ketoconazole and levoketoconazole include the nonsteroidal compound aminoglutethimide and the steroidal compound abiraterone acetate.

History

Ketoconazole was discovered in 1976 at Janssen Pharmaceuticals. It was patented in 1977, Oral ketoconazole has been replaced with oral fluconazole or itraconazole for many mycoses.

Due to incidence of serious liver toxicity, the use of oral ketoconazole was suspended in France in July 2011, following review. This event triggered an evaluation of oral ketoconazole throughout the rest of the European Union. In 2013, oral ketoconazole was withdrawn in the European Union and Australia, and strict restrictions were placed on the use of oral ketoconazole in the United States and Canada. Oral ketoconazole is indicated for use in these countries when the indication is a severe or life-threatening systemic infection and alternatives are unavailable. However, topical ketoconazole, which does not distribute systemically, is safe and widely used still.

Ketoconazole HRA was approved for use in the European Union for treatment of Cushing's syndrome in November 2013.

Society and culture

Generic names

Ketoconazole is the generic name of the drug and its , , , and .

Brand names

Ketoconazole has been marketed under a large number of brand names.

Availability

Ketoconazole is available widely throughout the world.

In 2013, the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) recommended that a ban be imposed on the use of oral ketoconazole for systemic use in humans throughout the European Union, after concluding that the risk of serious liver injury from systemic ketoconazole outweighs its benefits.

Research

As of March 2019, oral levoketoconazole (developmental code name COR-003, tentative brand name Recorlev) is phase III clinical trials for the treatment of Cushing's syndrome. Oral levoketoconazole may have a lower risk of liver toxicity than oral ketoconazole.

Veterinary use

Ketoconazole is sometimes prescribed as an antifungal by veterinarians for use in pets, often as unflavored tablets that may need to be cut to smaller size for correct dosage.

References

References

1. "Assessment report: Ketoconazole HRA". [[European Medicines Agency]] (EMA).
2. (February 2010). "Ketoconazole enantiomer for the treatment of diabetes mellitus". Expert Opinion on Investigational Drugs.
3. (18 September 2017). "Ketoconazole HRA 200mg Tablets - Summary of Product Characteristics (SmPC)".
4. (5 October 2015). "Ketoconazole 2% w/w Shampoo - Summary of Product Characteristics (SmPC)".
5. "Ketoconazole Monograph for Professionals". American Society of Health-System Pharmacists.
6. (2018). "British national formulary : BNF 76". Pharmaceutical Press.
7. (26 July 2013). "FDA limits usage of Nizoral (ketoconazole) oral tablets due to potentially fatal liver injury and risk of drug interactions and adrenal gland problems". [[U.S. Food and Drug Administration]].
8. (2006). "Analogue-based Drug Discovery". John Wiley & Sons.
9. "Ketoconazole Drug Usage Statistics, United States, 2013 - 2023".
10. (10 October 2013). "Oral ketoconazole (Nizoral) 200 mg tablets".
11. (25 June 2015). "国家食品药品监督管理总局关于停止生产销售使用酮康唑口服制剂的公告（2015年第85号）". [[China Food and Drug Administration]].
12. (2015). "The Rise and Fall of Oral Ketoconazole". [[Journal of Cutaneous Medicine and Surgery]].
13. (2013). "Comprehensive Dermatologic Therapy". Saunders.
14. (2012). "Dermatology". Saunders.
15. (2013). "Comprehensive Dermatologic Therapy". Saunders.
16. (2009). "Pharmacology". Lippincott Williams & Wilkins.
17. (2004). "Cecil Textbook of Medicine". Saunders.
18. (2001). "Principles and Practice of Endocrinology and Metabolism". Lippincott Williams & Wilkins.
19. (June 2012). "Promising therapies for treating and/or preventing androgenic alopecia". Skin Therapy Letter.
20. (1998). "Ketoconazole shampoo: effect of long-term use in androgenic alopecia". Dermatology.
21. (October 2002). "Nudging hair shedding by antidandruff shampoos. A comparison of 1% ketoconazole, 1% piroctone olamine and 1% zinc pyrithione formulations". International Journal of Cosmetic Science.
22. (August 2002). "Comparative efficacy of various treatment regimens for androgenetic alopecia in men". The Journal of Dermatology.
23. (December 2019). "Topical Antiandrogen Therapies for Androgenetic Alopecia and Acne Vulgaris". Am J Clin Dermatol.
24. (2019). "Trichogenic effect of topical ketoconazole versus minoxidil 2% in female pattern hair loss: A clinical and trichoscopic evaluation". Biomedical Dermatology.
25. "MedScape". Nature Publishing Group.
26. (May 1983). "Ketoconazole blocks adrenal steroidogenesis by inhibiting cytochrome P450-dependent enzymes". The Journal of Clinical Investigation.
27. (2008). "Cancer: Principles & Practice of Oncology". Lippincott Williams & Wilkins.
28. (December 1986). "Use of ketoconazole in the treatment of Cushing's syndrome". The Journal of Clinical Endocrinology and Metabolism.
29. (2001). "Flare Associated with LHRH-Agonist Therapy". Reviews in Urology.
30. "Ketoconazole (Nizoral) Use During Pregnancy".
31. (March 2005). "Population-based case-control study of oral ketoconazole treatment for birth outcomes". Congenital Anomalies.
32. (26 June 2018). "Ketoconazole tablet".
33. "Nizoral (Ketoconazole): Side Effects, Interactions, Warning, Dosage & Uses".
34. (December 1997). "Clinically significant azole cross-resistance in Candida isolates from HIV-positive patients with oral candidosis". AIDS.
35. (February 1997). "Cloning of Candida albicans genes conferring resistance to azole antifungal agents: characterization of CDR2, a new multidrug ABC transporter gene". Microbiology.
36. (May 1989). "Ketoconazole high dose in management of hormonally pretreated patients with progressive metastatic prostate cancer. Dutch South-Eastern Urological Cooperative Group". Urology.
37. (January 1996). "P450-dependent enzymes as targets for prostate cancer therapy". The Journal of Steroid Biochemistry and Molecular Biology.
38. (August 1992). "Ketoconazole binds to the human androgen receptor". Hormone and Metabolic Research.
39. (July 1983). "Ketoconazole binds to glucocorticoid receptors and exhibits glucocorticoid antagonist activity in cultured cells". The Journal of Clinical Investigation.
40. (July 2006). "Ketoconazole and miconazole are antagonists of the human glucocorticoid receptor: consequences on the expression and function of the constitutive androstane receptor and the pregnane X receptor". Molecular Pharmacology.
41. (November 1996). "Antiandrogen therapy in dermatology". International Journal of Dermatology.
42. (2010). "Reproductive Endocrinology and Infertility". Springer.
43. (2017). "Impacts of Medications on Male Fertility". Springer.
44. (November 1986). "Ketoconazole and other imidazole derivatives as inhibitors of steroidogenesis". Endocrine Reviews.
45. (August 1986). "The endocrine effects of ketoconazole". Journal of Endocrinological Investigation.
46. (May 1994). "Low dose ketoconazole attenuates serum androgen levels in patients with polycystic ovary syndrome and inhibits ovarian steroidogenesis in vitro". Fertility and Sterility.
47. (2009). "New endocrine drugs for treatment of advanced breast cancer". Acta Oncologica.
48. (1990). "Chemotherapy of Fungal Diseases". Springer.
49. (April 2018). "2+-Activated Monovalent Cation-Selective Channels". SLAS Discovery.
50. (August 1995). "Effects of an acidic beverage (Coca-Cola) on absorption of ketoconazole". Antimicrobial Agents and Chemotherapy.
51. (August 1979). "Antimycotic imidazoles. part 4. Synthesis and antifungal activity of ketoconazole, a new potent orally active broad-spectrum antifungal agent". Journal of Medicinal Chemistry.
52. (19 April 2016). "Drug Therapy in Dermatology". CRC Press.
53. William Andrew Publishing. (22 October 2013). "Pharmaceutical Manufacturing Encyclopedia". Elsevier.
54. (25 July 2013). "Ketoconazole-containing medicines". [[European Medicines Agency]] (EMA).
55. (23 April 2012). "Ketoconazole HRA EPAR". [[European Medicines Agency]] (EMA).
56. (26 September 2014). "Ketoconazole HRA recommended for approval in Cushing's syndrome". [[European Medicines Agency]] (EMA).
57. (14 November 2014). "The Dictionary of Drugs: Chemical Data: Chemical Data, Structures and Bibliographies". Springer.
58. (2000). "Index Nominum 2000: International Drug Directory". Taylor & Francis.
59. (6 December 2012). "Concise Dictionary of Pharmacological Agents: Properties and Synonyms". Springer Science & Business Media.
60. "Ketoconazole".
61. (26 July 2013). "European Medicines Agency recommends suspension of marketing authorisations for oral ketoconazole". [[European Medicines Agency]] (EMA).
62. "Levoketoconazole - Strongbridge Biopharma - AdisInsight".
63. (December 2016). "Updates on the role of adrenal steroidogenesis inhibitors in Cushing's syndrome: a focus on novel therapies". Pituitary.
64. (January 2008). "A review of selected systemic antifungal drugs for use in dogs and cats". Veterinary Medicine.